0.47 | 1.09%
| Price and Volume | |
|---|---|
| Recent Price | 43.24 |
| 52 Week High | 44.24 |
| 52 Week Low | 25.94 |
| Avg. Daily Vol. (Mil) | 1.47 |
| Beta (3 year) | 0.45 |
| Share Related Items | |
| Mkt Cap (Mil) | 8,672.92 |
| Shares Out (Mil) | 200.58 |
| Float (Mil) | 178.36 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 4.50 |
| Current Ratio | 4.60 |
| LT Debt/ Equity | 0.11 |
| Total Debt / Equity | 0.14 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 85.12 |
| Price/Book | 7.91 |
| Price/Cash Flow | -14.20 |
| Per Share Data | |
| Earnings | -3.71 |
| Sales | 0.51 |
| Book Value | 5.47 |
| Cash Flow | -3.04 |
| Business Summary | |
|---|---|
| The Company is is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. | |
| General Information | |
| 130 Waverly Street
Cambridge, MA 02139-4242 |
|
| www.vpharm.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 1422 | |
| CEO: Matthew W. Emmens | |
| Short Interest | |
| Current Month (Mil) | 17.68 |
| Previous Month (Mil) | 16.85 |
| Short Interest Ratio (Days) | 11.80 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -32.80 |
| Return on Investments | -52.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,685.98 | 1,159.46 | 2,378.01 | 36.53 |
Oil *
79.02
|
|
UP
43.83
|
UP
8.95
|
UP
15.80
|
DOWN
0.51
|
10 Yr
3.65%
SPDR Gold
110.40
|
|
+0.41%
|
+0.78%
|
+0.67%
|
-1.38%
|
Data delayed 20 minutes |
Connect with TheStreet